Posted by Michael Wonder on 15 Dec 2022
Dupixent (dupilumab) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularis
15 December 2022 - Approval based on direct to Phase 3 program showing more than three times as many Dupixent patients experienced a clinically meaningful reduction in itch at 24 weeks.
The European Commission has expanded the marketing authorisation for Dupixent (dupilumab) in the European Union to treat adults with moderate to severe prurigo nodularis who are candidates for systemic therapy.
